Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Afternoon Napping, Caffeine and Recovery on Evening Athletic Performance (NAP-CAF-REC)

16 czerwca 2026 zaktualizowane przez: Kais Elabed, The Higher Institute of Sport and Physical Education of Sfax

Effects of Afternoon Napping, Caffeine and Personalised Recovery Protocol on Evening Athletic Performance According to Sex and Chronotype: A Randomised Crossover Trial

This study investigates the effects of napping, caffeine, and a personalised recovery protocol on evening athletic performance in male and female athletes.

Background: Evening athletic performance can be impaired by accumulated sleepiness and natural circadian rhythms. Athletes often seek strategies to maintain peak performance during evening competitions. Napping, caffeine, and recovery protocols are commonly used but their combined effects, particularly differences between sexes and chronotypes (morning-type vs evening-type individuals), remain unclear.

Objective: To determine whether combining a 90-minute afternoon nap with moderate caffeine ingestion (5 mg/kg) and a brief personalised recovery protocol (dynamic stretching plus carbohydrate-protein snack) produces superior evening performance compared to each intervention alone.

Methods: Sixty elite university athletes (30 males, 30 females) will participate in a randomised, double-blind, placebo-controlled crossover trial. Each participant will complete five experimental conditions separated by at least 72 hours: (1) placebo, (2) nap alone, (3) caffeine alone, (4) nap plus caffeine, and (5) nap plus caffeine plus recovery protocol. Performance will be assessed at 19:00 using tests of agility, jumping, sprinting, and reaction time. Physiological measurements including heart rate variability, salivary cortisol, plasma brain-derived neurotrophic factor (BDNF), and blood lactate will be collected at multiple timepoints.

Expected Outcomes: The combined intervention (nap plus caffeine plus recovery) is expected to produce the greatest improvements in physical and cognitive performance, with potential differences between males and females and between morning-type and evening-type athletes.

Significance: Findings will provide evidence-based recommendations for athletes and coaches seeking to optimise evening performance through multi-modal strategies.

Przegląd badań

Szczegółowy opis

This is a mechanistic, randomised, double-blind, placebo-controlled crossover trial designed to examine the isolated and combined effects of afternoon napping, caffeine ingestion, and a personalised active recovery protocol on evening cognitive and physical performance in male and female athletes stratified by chronotype.

STUDY DESIGN:

The study employs a Latin square counterbalanced crossover design with five experimental conditions separated by washout periods of at least 72 hours to eliminate carryover effects of caffeine and sleep manipulation:

  1. PLA: Placebo capsule at 18:00, no nap opportunity
  2. NAP: 90-min nap opportunity (13:00-14:30) + placebo capsule at 18:00
  3. CAF: Caffeine ingestion (5 mg/kg anhydrous caffeine) at 18:00, no nap opportunity
  4. NAP+CAF: 90-min nap + caffeine (5 mg/kg) at 18:00
  5. NAP+CAF+REC: 90-min nap + caffeine (5 mg/kg) at 18:00 + 15-min personalised active recovery protocol (dynamic stretching + carbohydrate-protein snack) from 18:45-19:00

Condition allocation was determined using a Latin square design separately for each combination of sex and chronotype (morning-type males, evening-type males, morning-type females, evening-type females). Condition allocation was concealed in sequentially numbered, opaque, sealed envelopes prepared by an independent researcher not involved in data collection. Both participants and the experimenters responsible for testing were blinded to condition assignment. Capsules were prepared by an independent pharmacist and were identical in appearance, mass, colour, and odour. The researcher administering the capsules and the one preparing the EEG and biomarker materials were different from the testing team to ensure blinding.

PARTICIPANTS:

Sixty elite university athletes (30 males, 30 females; age 20.6 ± 1.5 years) were recruited from the Higher Institute of Sport and Physical Education of Sfax, Tunisia, and from regional sport clubs. Participants were classified as definite morning-type (MEQ score 59-86) or definite evening-type (MEQ score 16-41) using the Morningness-Eveningness Questionnaire, with exclusion of intermediate types (score 42-58) to maximise contrast between chronotype groups. Female participants were tested during the early follicular phase of the menstrual cycle (days 2-5) to control for hormonal variability.

EXPERIMENTAL PROCEDURES:

Participants arrived at the laboratory at 19:00 on the evening before each trial for standardisation. They consumed a standardised dinner (35 kcal/kg, 55% carbohydrates, 15% protein, 30% fat) at 20:00, followed by two hours of low-demand leisure activities. Lights were turned off at 22:15 after a 10-min adaptation period in a darkened, sound-attenuated room, and wake-up time was fixed at 06:30. Sleep duration was confirmed by wrist actigraphy and sleep diaries; only nights with total sleep time between 7.5 and 8.5 hours were accepted. A standardised breakfast (20 kcal/kg, 65% carbohydrates, 15% protein, 20% fat) was provided at 07:00.

Throughout the morning, participants remained in the laboratory and engaged exclusively in sedentary activities (reading, quiet games, internet browsing) to avoid unplanned physical exertion. At 12:00, they consumed a standardised isocaloric lunch (35 kcal/kg, 55% carbohydrates, 15% protein, 30% fat).

In nap conditions (NAP, NAP+CAF, NAP+CAF+REC), participants entered the nap room at 12:50 and were fitted with a portable EEG headband (Dreem 3, Dreem, Paris, France) for objective sleep recording. Earplugs and eye masks were provided, and the nap opportunity commenced at 13:00 for a duration of 90 minutes (until 14:30). The room was maintained quiet (ambient noise < 30 dB), dimly lit (< 10 lux), and at a constant temperature (22 ± 1°C). Awakening was by a silent vibrating alarm placed under the pillow to avoid startling. For the no-nap conditions (PLA and CAF), participants remained in a quiet, dimly lit room and engaged in passive activities (reading, quiet games) during the same 13:00-14:30 time window without lying down.

After the nap or rest period, participants remained in the laboratory and continued with passive, seated activities until 18:00. At 18:00, participants ingested a single opaque capsule containing either anhydrous caffeine powder (5 mg/kg of body mass) or a visually identical placebo (microcrystalline cellulose-starch mixture). All capsules were swallowed with 200 mL of still water under direct supervision to ensure compliance.

In the NAP+CAF+REC condition only, participants underwent a 15-min personalised active recovery protocol from 18:45 to 19:00, consisting of five dynamic stretching exercises targeting the lower limb musculature (leg swings, walking lunges, high knees, butt kicks), each performed for 10 repetitions per leg, followed by a carbohydrate-protein snack (30 g total, 2:1 carbohydrate-to-protein ratio: 20 g maltodextrin + 10 g whey isolate mixed with 200 mL water, 120 kcal).

At 19:00, all participants completed a standardised 10-min warm-up consisting of light jogging (5 min at a self-selected pace), five submaximal vertical jumps, and dynamic stretching. This was followed by a 5-min passive rest period, then the testing battery performed in fixed order (19:15-20:00).

STATISTICAL ANALYSIS:

Linear mixed-effects models will be fitted with fixed effects for sex, chronotype, condition, timepoint (where applicable), and their interactions, with random intercepts for subject. Degrees of freedom and p-values will be estimated using the Kenward-Roger approximation. Model fit will be assessed using conditional R². Post-hoc pairwise comparisons will use Bonferroni correction. Significance level: p ≤ 0.01 (adjusted for multiple comparisons across five conditions). Effect sizes: partial eta-squared (ηp²) for ANOVA effects and Cohen's d for pairwise comparisons. Sample size calculation (G*Power 3.1.9.7): based on repeated agility performance (ηp² = 0.14, effect size f = 0.40, α = 0.01, power = 0.95, two groups sex, two groups chronotype, five repeated measures, correlation between repeated measures = 0.5, nonsphericity correction ε = 1), minimum n = 56. With 10% dropout allowance, n = 60 will be recruited.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

60

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Sfax, Tunezja, 3000
        • Higher Institute of Sport and Physical Education of Sfax (ISSEP Sfax)

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Tak

Opis

Inclusion Criteria:

  • Regular engagement in at least 10 two-hour training sessions per week across various sports (team sports, judo, track and field, tennis, swimming)
  • Non-habitual napping (fewer than one nap per week)
  • Caffeine-naïve (habitual daily caffeine intake < 80 mg, verified by a 7-day dietary recall)
  • Non-smokers and free from any regular medication or recreational drugs
  • Free from any musculoskeletal injury in the previous month
  • Normal sleep quality (Pittsburgh Sleep Quality Index score < 5)
  • Classified as either definite morning-type (MEQ score 59-86) or definite evening-type (MEQ score 16-41) on the Morningness-Eveningness Questionnaire
  • For female participants: eumenorrheic (regular menstrual cycle length 26-32 days), not using hormonal contraceptives, and no history of menstrual disorders

Exclusion Criteria:

  • Intermediate chronotype (MEQ score 42-58)
  • Habitual nappers (≥1 nap per week)
  • High habitual caffeine intake (≥80 mg/day)
  • Current use of any medication or recreational drugs
  • Smokers
  • Musculoskeletal injury within the previous month
  • Poor sleep quality (PSQI score ≥ 5)
  • Irregular menstrual cycle or use of hormonal contraceptives (for female participants)
  • History of sleep disorders (e.g., insomnia, sleep apnea)
  • Inability to complete all five experimental conditions

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: PLA
Placebo capsule (microcrystalline cellulose) at 18:00, no nap opportunity
Microcrystalline cellulose powder administered in opaque capsules at 18:00. Capsules were visually identical in appearance, mass, color, and odor to caffeine capsules.
Eksperymentalny: NAP
90-minute afternoon nap opportunity (13:00-14:30) with objective sleep architecture recording via portable EEG headband (Dreem 3), followed by placebo capsule (microcrystalline cellulose) at 18:00. Participants remained in a quiet, dimly lit room during the nap opportunity.
Microcrystalline cellulose powder administered in opaque capsules at 18:00. Capsules were visually identical in appearance, mass, color, and odor to caffeine capsules.
90-minute afternoon nap opportunity (13:00-14:30) in a quiet, dimly lit room with objective sleep architecture monitoring using portable EEG headband (Dreem 3). Participants wore earplugs and eye masks. Sleep stages (N1, N2, N3, REM) were recorded.
Eksperymentalny: CAF
Caffeine ingestion (5 mg/kg body mass of anhydrous caffeine) at 18:00, no nap opportunity. Participants remained in a quiet, dimly lit room during the 13:00-14:30 period.
Anhydrous caffeine powder (5 mg per kg of body mass) administered in opaque capsules at 18:00. Capsules were visually identical to placebo capsules (microcrystalline cellulose). This dose is within the range of common dietary caffeine intake and is classified as a nutritional supplement.
Eksperymentalny: NAP+CAF
90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, followed by caffeine ingestion (5 mg/kg) at 18:00.
90-minute afternoon nap opportunity (13:00-14:30) in a quiet, dimly lit room with objective sleep architecture monitoring using portable EEG headband (Dreem 3). Participants wore earplugs and eye masks. Sleep stages (N1, N2, N3, REM) were recorded.
Anhydrous caffeine powder (5 mg per kg of body mass) administered in opaque capsules at 18:00. Capsules were visually identical to placebo capsules (microcrystalline cellulose). This dose is within the range of common dietary caffeine intake and is classified as a nutritional supplement.
Eksperymentalny: NAP+CAF+REC
90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, caffeine ingestion (5 mg/kg) at 18:00, plus 15-minute personalised active recovery protocol (18:45-19:00) consisting of dynamic stretching and a carbohydrate-protein snack (20g maltodextrin + 10g whey isolate).
90-minute afternoon nap opportunity (13:00-14:30) in a quiet, dimly lit room with objective sleep architecture monitoring using portable EEG headband (Dreem 3). Participants wore earplugs and eye masks. Sleep stages (N1, N2, N3, REM) were recorded.
Anhydrous caffeine powder (5 mg per kg of body mass) administered in opaque capsules at 18:00. Capsules were visually identical to placebo capsules (microcrystalline cellulose). This dose is within the range of common dietary caffeine intake and is classified as a nutritional supplement.
15-minute active recovery protocol (18:45-19:00) consisting of: (1) dynamic stretching exercises targeting lower limb musculature (leg swings, walking lunges, high knees, butt kicks; 10 repetitions per leg), followed by (2) consumption of a carbohydrate-protein snack (30g total: 20g maltodextrin + 10g whey isolate, 2:1 ratio) mixed with 200mL water.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Repeated Modified Agility Test (RMAT) Total Time
Ramy czasowe: Measured at 19:45 (immediately after the testing battery) on each of the 5 experimental days
Total time (seconds) to complete 10 maximal 20-m sprints with four changes of direction (forward sprint, left shuffle, right shuffle, backward sprint). The test was conducted on an indoor hardwood court using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start/finish line. Participants started from a standing position 0.5 m behind the first photocell. Lower values indicate better repeated agility performance. This was the primary outcome measure used for sample size calculation.
Measured at 19:45 (immediately after the testing battery) on each of the 5 experimental days

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Countermovement Jump (CMJ) Height
Ramy czasowe: Measured at approximately 19:30 during the post-testing battery on each of the 5 experimental days
Maximum jump height (cm) calculated from flight time using the formula h = g·t²/8, where g = 9.81 m·s-². Participants started from an upright standing position, performed a rapid downward movement to approximately 90° knee flexion, and immediately jumped vertically, maintaining hands on hips throughout. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained. Measured using an optical measurement system (Optojump Next, Microgate SRL, Bolzano, Italy) with a sampling frequency of 1000 Hz. Higher values indicate better explosive lower-limb performance.
Measured at approximately 19:30 during the post-testing battery on each of the 5 experimental days
Squat Jump (SJ) Height
Ramy czasowe: Measured at approximately 19:35 during the post-testing battery on each of the 5 experimental days
Maximum jump height (cm) from a static squat position with knees at approximately 90° flexion, hands on hips. Participants held the starting position for 2-3 seconds before jumping vertically without any countermovement. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained for analysis. Calculated from flight time using h = g·t²/8. Measured using Optojump Next optical system (1000 Hz sampling frequency). Higher values indicate better explosive lower-limb performance without stretch-shortening cycle contribution.
Measured at approximately 19:35 during the post-testing battery on each of the 5 experimental days
20-m Sprint Time
Ramy czasowe: Measured at approximately 19:40 during the post-testing battery on each of the 5 experimental days
Best time (seconds) of two maximal 20-m sprints from a standing start, with 3 minutes of passive recovery between sprints. Participants started 0.5 m behind the start line. Sprint time was measured using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start (0 m) and finish (20 m) lines. Lower values indicate better linear sprint performance.
Measured at approximately 19:40 during the post-testing battery on each of the 5 experimental days
Simple Reaction Time (SRT)
Ramy czasowe: Measured at approximately 19:15 (first test in the battery) on each of the 5 experimental days
Mean reaction time (milliseconds) across 15 recorded trials. A green circle appeared on a black background on a 15-inch laptop screen (60 Hz refresh rate), and participants pressed the space bar as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster simple reaction time and better cognitive processing speed.
Measured at approximately 19:15 (first test in the battery) on each of the 5 experimental days
Choice Reaction Time (CRT)
Ramy czasowe: Measured at approximately 19:20 (second test in the battery) on each of the 5 experimental days
Mean reaction time (milliseconds) across 15 recorded trials. Either a red circle (press the left arrow key) or a blue square (press the right arrow key) appeared randomly on a 15-inch laptop screen (60 Hz refresh rate). Participants had to identify the stimulus and press the correct key as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster choice reaction time and better cognitive decision-making speed.
Measured at approximately 19:20 (second test in the battery) on each of the 5 experimental days
Heart Rate Variability (HRV-RMSSD)
Ramy czasowe: Measured at three timepoints on each experimental day: baseline (12:00), pre-intervention (18:00), and post-testing (19:45)
Time-domain and frequency-domain parameters of heart rate variability recorded during 5 minutes in a supine resting position with spontaneous breathing. RR intervals were measured using a Polar H10 chest strap (Polar Electro, Kempele, Finland) with 1000 Hz sampling frequency. Primary parameter: RMSSD (root mean square of successive differences between normal heartbeats, in ms). Secondary parameter: HF power (high-frequency power, 0.15-0.40 Hz, in normalized units). Data were analyzed using Kubios HRV software (version 3.5) with artefact correction. Higher RMSSD values indicate greater parasympathetic (vagal) activity and better autonomic recovery.
Measured at three timepoints on each experimental day: baseline (12:00), pre-intervention (18:00), and post-testing (19:45)
Salivary Cortisol Concentration
Ramy czasowe: Measured at four timepoints on each experimental day: baseline (12:00), pre-intervention (18:00), post-testing (19:45), and 30 minutes post-exercise (20:30)
Salivary cortisol concentration (nmol/L) measured using Salivette cotton swabs (Sarstedt, Nümbrecht, Germany). Participants were instructed to avoid eating, drinking (except water), and brushing teeth for 30 minutes before each sample. Samples were centrifuged at 1500×g for 10 minutes at 4°C, and the supernatant was stored at -80°C until analysis. Cortisol concentration was measured in duplicate using a high-sensitivity enzyme-linked immunosorbent assay (ELISA, IBL International, Hamburg, Germany) with a detection limit of 0.05 ng/mL and intra- and inter-assay coefficients of variation < 8%. Lower values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activity.
Measured at four timepoints on each experimental day: baseline (12:00), pre-intervention (18:00), post-testing (19:45), and 30 minutes post-exercise (20:30)
Plasma Brain-Derived Neurotrophic Factor (BDNF)
Ramy czasowe: Measured at two timepoints on each experimental day: baseline (12:00) and post-testing (19:45)
BDNF concentration (pg/mL) measured in venous blood samples (5 mL) drawn from an antecubital vein. Blood was collected into EDTA tubes, immediately centrifuged at 1500×g for 15 minutes at 4°C, and plasma was stored at -80°C until analysis. BDNF concentration was quantified using a commercially available ELISA kit (R&D Systems, Minneapolis, MN, USA; catalogue number DBD00) with a detection limit of 20 pg/mL and intra- and inter-assay CVs < 6% and < 9%, respectively. Higher values indicate greater neurotrophic activity.
Measured at two timepoints on each experimental day: baseline (12:00) and post-testing (19:45)
Blood Lactate Concentration
Ramy czasowe: Measured at three timepoints on each experimental day: pre-warm-up (18:55), 3 minutes post-RMAT, and 3 minutes post-20m sprint
Lactate concentration (mmol/L) measured in capillary blood samples (5 µL) collected from the fingertip using a Lactate Pro 2 analyzer (Arkray, Kyoto, Japan), which has a coefficient of variation < 3%. Higher values indicate greater metabolic perturbation and glycolytic activation during high-intensity exercise.
Measured at three timepoints on each experimental day: pre-warm-up (18:55), 3 minutes post-RMAT, and 3 minutes post-20m sprint
Nap Architecture (EEG)
Ramy czasowe: Recorded during the 90-minute nap opportunity (13:00-14:30) on NAP, NAP+CAF, and NAP+CAF+REC conditions only
Objective sleep parameters recorded using a validated dry-electrode portable EEG headband (Dreem 3, Paris, France) with six channels (F3, F4, C3, C4, O1, O2, referenced to linked mastoids). Sleep stages were automatically scored in 30-second epochs using the manufacturer's algorithm and visually corrected by a certified sleep technologist blinded to condition and participant. Parameters extracted: total sleep time (TST, minutes), sleep onset latency (SOL, minutes), time in N2 sleep (minutes), time in N3 slow-wave sleep (minutes), time in REM sleep (minutes), and sleep efficiency (TST/time in bed × 100, %).
Recorded during the 90-minute nap opportunity (13:00-14:30) on NAP, NAP+CAF, and NAP+CAF+REC conditions only

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Kais El Abed, Phd, University of Sfax, Tunisia

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

2 stycznia 2025

Zakończenie podstawowe (Rzeczywisty)

31 maja 2025

Ukończenie studiów (Rzeczywisty)

31 maja 2025

Daty rejestracji na studia

Pierwszy przesłany

10 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

17 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Anonymised individual participant data (IPD) will be shared for all 60 participants across all five experimental conditions (300 experimental sessions). Data will include: demographic characteristics, anthropometric measures, chronotype classification (MEQ scores), sleep quality (PSQI scores), nap architecture (EEG-derived sleep stages), physical performance outcomes (RMAT, CMJ, SJ, 20-m sprint), cognitive performance outcomes (SRT, CRT), subjective sleepiness (ESS, KSS), and physiological biomarkers (HRV-RMSSD, HF power, salivary cortisol, plasma BDNF, blood lactate). All data will be fully anonymised using coded identifiers (S01-S60), with the identification key stored separately on encrypted institutional servers.

Ramy czasowe udostępniania IPD

IPD and supporting information are currently available on the Open Science Framework (OSF) repository at https://osf.io/3wq5j/. The dataset includes anonymised individual participant data (n=60, 300 experimental sessions), the R statistical analysis script, and the ethical approval certificate. Data will remain accessible indefinitely. Upon publication of the study results in a peer-reviewed journal, additional supporting documents (study protocol, statistical analysis plan, and informed consent form) will be added to the repository.

Kryteria dostępu do udostępniania IPD

The anonymised IPD and supporting documents will be openly accessible to any researcher, clinician, or member of the public without restriction. No formal request process or approval is required. Users may download the data directly from the Open Science Framework (OSF) repository once deposited. Researchers who reuse the data are requested to cite the original publication and the OSF dataset DOI. The data are provided "as is" without any warranty or guarantee of accuracy.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF
  • ANALITYCZNY_KOD

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Placebo

Subskrybuj